Cover Image
市場調查報告書

多發性囊胞腎 (PKD) 治療藥的開發平台分析:臨床實驗·結果,專利,指定,聯盟,其他趨勢

Polycystic Kidney Disease (PKD) Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 600266
出版日期 內容資訊 英文 86 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性囊胞腎 (PKD) 治療藥的開發平台分析:臨床實驗·結果,專利,指定,聯盟,其他趨勢 Polycystic Kidney Disease (PKD) Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
出版日期: 2017年11月01日 內容資訊: 英文 86 Pages
簡介

本報告提供多發性囊胞腎 (PKD) 治療藥開發平台調查分析,提供不同階段分析,臨床實驗分析,競爭情形分析,企業簡介等系統性資訊。

第1章 調查背景

第2章 調查手法

第3章 摘要整理

第4章 開發平台預測

  • 概要
  • 主要促進因素
  • 主要障礙
  • 開發平台分析

第5章 開發平台分析:不同階段

  • 申請:藥物簡介
  • 階段II:藥物簡介
  • 階段I:藥物簡介
  • 前臨床:藥物簡介
  • 藥物研發:藥物簡介
  • 休止:藥物簡介

第6章 臨床實驗分析

  • 臨床實驗:各地區
  • 臨床實驗:各狀況

第7章 競爭情形分析

  • 主要企業基準
  • SWOT分析

第8章 企業簡介

  • 產業概要
  • 提供之產品與服務

第9章 附錄

目錄

polycystic kidney disease currently exhibits a growing pipeline with approximately 16 drug candidates, According to P&S Market Research

Polycystic Kidney Disease Pipeline in 2017

The study analyzed that the polycystic kidney disease (PKD) therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. PKD affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. The disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. People with PKD are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. The disease can be categorized into two types, as autosomal dominant polycystic kidney disease (AKPKD), and autosomal recessive polycystic kidney disease (ARPKD). AKPKD generally diagnosed in adulthood, while ARPKD diagnosed in earliest months of life.

Insights on pipeline segments

According to the research findings, most of the drug candidates of the PKD are being developed to be administered by the oral route.

Surge in the development of Pre-Clinical and Discovery Drug Candidates

Many pharmaceutical companies are involved in the development of therapeutic compounds by overcoming the challenges, that are effective in the treatment of PKD. They are focusing on developing the maximum drug candidates in the Pre-Clinical and Discovery stage of development. The pipeline consists of approximately eight drug candidates in the Pre-Clinical stage. GLG Pharma is in the process of developing two drug candidates in Pre-Clinical stage.

Increased Funding by the Government Organizations Contributing Immensely in Pipeline Growth

Novatarg Pharmaceuticals, received $3.2 million funding by Small Business Innovation Research (SBIR), a part of governmental agencies of National Institutes of Health, to further conduct clinical study in PKD. Novatarg Pharmaceuticals, is in the process of research and development activities of NT 1044. Through the funding, NovaTarg Pharmaceuticals had further planned to progress drug candidates for PKD and type II diabetes mellitus. In addition, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is also supporting the pharmaceutical companies to conduct clinical study and research on PKD to improve patient health.

Some of the key players developing drugs for the treatment of PKD therapeutics include Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., and XORTX Pharma Corp.

Polycystic Kidney Disease Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
  • 4.2 Key Drivers
  • 4.3 Key Barriers
  • 4.4 Polycystic Kidney Diseases Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Polycystic Kidney Diseases Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Filed: Drug profiles
    • 5.1.1 Pre-Clinical Study
    • 5.1.2 Pre-Clinical Results
    • 5.1.3 Clinical Trials
    • 5.1.4 Clinical Results
    • 5.1.5 Strategic Development
    • 5.1.6 Designation
    • 5.1.7 Grants
    • 5.1.8 Patent
    • 5.1.9 Technology
  • 5.2 Phase II: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology
  • 5.3 Phase I: Drug profiles
    • 5.3.1 Pre-Clinical Study
    • 5.3.2 Pre-Clinical Results
    • 5.3.3 Clinical Trials
    • 5.3.4 Clinical Results
    • 5.3.5 Strategic Development
    • 5.3.6 Designation
    • 5.3.7 Grants
    • 5.3.8 Patent
    • 5.3.9 Technology
  • 5.4 Pre-Clinical: Drug profiles
    • 5.4.1 Pre-Clinical Study
    • 5.4.2 Pre-Clinical Results
    • 5.4.3 Strategic Development
    • 5.4.4 Designation
    • 5.4.5 Grants
    • 5.4.6 Patent
    • 5.4.7 Technology
  • 5.5 Discovery: Drug profiles
    • 5.5.1 Strategic Development
    • 5.5.2 Designation
    • 5.5.3 Grants
    • 5.5.4 Patent
    • 5.5.5 Technology
  • 5.6 Inactive: Drug profiles
    • 5.6.1 Pre-Clinical Study
    • 5.6.2 Pre-Clinical Results
    • 5.6.3 Clinical Trials
    • 5.6.4 Clinical Results
    • 5.6.5 Strategic Development
    • 5.6.6 Designation
    • 5.6.7 Grants
    • 5.6.8 Patent
    • 5.6.9 Technology

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region
  • 6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Polycystic Kidney Disease Therapeutics Pipeline
  • 7.2 SWOT Analysis of Polycystic Kidney Disease Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Business Overview
  • 8.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • PIPELINE ANALYSIS OF POLYCYSTIC KIDNEY DISEASE THERAPEUTICS, BY COMPANY (2017)
  • DESCRIPTION OF FILED STGAE DRUG CANDIDATES
  • CLINICAL TRIALS OF FILED STGAE DRUG CANDIDATES
  • DESCRIPTION OF PHASE II DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
  • DESCRIPTION OF PHASE I DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
  • DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
  • DESCRIPTION OF DISCOVERY DRUG CANDIDATES
  • DESCRIPTION OF INACTIVE DRUG CANDIDATES
  • COMPANIES - AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • BREAKDOWN OF PRIMARY RESEARCHBY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCHBY COMPANY TYPE
  • POLYCYSTIC KIDNEY DISEASES THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • POLYCYSTIC KIDNEY DISEEASE THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • POLYCYSTIC KIDNEY DISEASE THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING
  • SWOT ANALYSIS
Back to Top